- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05685732
An Efficacy and Safety Study w/ Azstarys® in Children With ADHD (KP415P01)
January 4, 2024 updated by: Corium, Inc.
A Multicenter, Dose-Optimized, Randomized, Double Blind, Efficacy and Safety Study With Azstarys® in Children 4 to 12 Years of Age With Attention Deficit/Hyperactivity Disorder
This is a multicenter, dose-optimized, randomized, double-blind, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
Azstarys® contains dexmethylphenidate (d-MPH) and serdexmethylphenidate (SDX), a prodrug of d-MPH and is orally adminstered.
The primary objective is to determine the efficacy of Azstarys® compared to placebo in treating children ages 4 to 12 years old with ADHD.
The study will consist of two randomized and blinded treatment cohorts ages 4 to 5 years of age and 6 to 12 years of age.
130 and 100 subjects will be enrolled respectively.
Approximately 20 sites will participate.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
- Screening Period (Visit 1) Subjects will undergo a screening period up to 30 days prior to entering the Treatment Period.
Double-Blind Treatment Period (Visit 2 through Visit 6) Eligible subjects will be randomized in a blinded fashion to Azstarys® or placebo at the start of the Treatment Period. Randomization will be applied separately in each cohort and stratified by gender.
- Cohort 1: Subjects 4 and 5 years (<6 years) will start at 13.1 mg/2.6 mg or matching placebo and may be titrated up or down to doses of 13.1 mg/2.6 mg, 26.1 mg/5.2 mg, or 39.2 mg/7.8 mg Azstarys® or matching placebo approximately each week through Visit 5
- Cohort 2: Subjects 6-12 years (<13 years) will start at 39.2 mg/7.8 mg or matching placebo and may be titrated up or down to doses of 26.1 mg/5.2 mg, 39.2 mg/7.8 mg, or 52.3 mg/10.4 mg Azstarys® or matching placebo approximately each week through Visit 5
Study Type
Interventional
Enrollment (Estimated)
230
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Charles Oh, MD
- Phone Number: 857-331-7950
- Email: coh@corium.com
Study Contact Backup
- Name: Ron Tashjian
- Phone Number: 6172337474
- Email: rtashjian@corium.com
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Recruiting
- Preferred Research Partners (PRP)
-
Principal Investigator:
- Renea Henderson, MD
-
Contact:
- Emily Knight
- Phone Number: 501-553-9987
- Email: EKnight@preferredresearchpartners.com
-
-
California
-
Anaheim, California, United States, 92805
- Recruiting
- Advanced Research Center (ARC)
-
Principal Investigator:
- Rennan Quijano, MD
-
Contact:
- Britney Nguyen
- Phone Number: 714-999-6688
- Email: britney.nguyen@arctrials.com
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Recruiting
- IMMUNOe International Research Center
-
Principal Investigator:
- Joe Williams, MD
-
Contact:
- Catherine Powell
- Phone Number: 303-771-9000
- Email: cpowell@immunoeresearch.com
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Recruiting
- Clinical Neuroscience Solutions - Jacksonville
-
Principal Investigator:
- Nandita Jones, MD
-
Contact:
- Leticia Goodwin
- Phone Number: 904-281-5757
- Email: lgoodwin@cnshealthcare.com
-
Lakeland, Florida, United States, 33803
- Recruiting
- Accel Research Sites - Lakeland
-
Contact:
- Colleen Figueroa
- Phone Number: 863-940-2087
- Email: cfigueroa@accelclinical.com
-
Principal Investigator:
- Rosa Negron, MD
-
Maitland, Florida, United States, 32751
- Recruiting
- Accel Research Sites - Maitland
-
Principal Investigator:
- Andrea Marraffino, Ph.D
-
Contact:
- Lisa Houle
- Phone Number: 407-644-1165
- Email: lhoule@accelclinical.com
-
Miami Springs, Florida, United States, 33166
- Recruiting
- South Florida Research Phase I-IV Inc
-
Contact:
- Lisbelle Revoredo
- Phone Number: 305-418-0847
- Email: lrevoredo@southfloridatrials.com
-
Principal Investigator:
- Silvia S Duluc, MD
-
Orlando, Florida, United States, 32801
- Recruiting
- CNS Healthcare - Orlando
-
Principal Investigator:
- Robert Molpus, MD
-
Contact:
- Ashley Westerfield
- Phone Number: 407-425-5100
- Email: awesterfeld@cnshealthcare.com
-
-
Georgia
-
Atlanta, Georgia, United States, 30339
- Recruiting
- Sky Clinical Research Network Group P.C.
-
Principal Investigator:
- Yvonne Smith, MD
-
Contact:
- Carnisha Williams
- Phone Number: 470-317-3604
- Email: carnisha.williams@skycrng.com
-
Decatur, Georgia, United States, 30030
- Recruiting
- CenExel IResearch, LLC - Decatur
-
Principal Investigator:
- Kimball Johnson, MS
-
Contact:
- Abel Beck
- Phone Number: 404-537-1281
- Email: a.beck@cenexel.com
-
Savannah, Georgia, United States, 31405
- Recruiting
- CenExel iResearch, LLC
-
Contact:
- Susan Shuman
- Phone Number: 912-722-0800
- Email: s.shuman@cenexel.com
-
Principal Investigator:
- Yael Elfassy, MS
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Recruiting
- Delricht Research - Touro Medical Center
-
Principal Investigator:
- Caroline Campion, MD
-
Contact:
- Juliana Laurent
- Phone Number: 504-336-2667
- Email: jlaurent@delricht.com
-
-
Missouri
-
Saint Charles, Missouri, United States, 80112
- Recruiting
- St Charles Psychiatric Associates & Midwest Research Group
-
Principal Investigator:
- Gregory Mattingly, MD
-
Contact:
- Chritian Majewski
- Phone Number: 636-946-8032
- Email: cmajewski@midwestresearchgroup.com
-
-
Montana
-
Missoula, Montana, United States, 75093
- Recruiting
- Boeson Research
-
Principal Investigator:
- Merlin Fausett, Ph.D
-
Contact:
- Mandi Hansmeyer
- Phone Number: 406-763-8833
- Email: mandi@boesonresearch.com
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Recruiting
- Alivation Research, LLC
-
Contact:
- Katy Boman
- Phone Number: 402-817-2235
- Email: kboman@alivation.com
-
Principal Investigator:
- Walter Duffy, MD
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Recruiting
- Center for Psychiatry and Behavioral Medicine Inc
-
Contact:
- Randi Lambert
- Phone Number: 702-838-0742
- Email: Randi.lampert@gmail.com
-
Principal Investigator:
- Ann Childress, MD
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Recruiting
- Clinical Neuroscience Solutions--Memphis
-
Principal Investigator:
- Valerie Arnold, MD
-
Contact:
- Anthony Codi
- Phone Number: 901-843-1045
- Email: canthony@cnshealthcare.com
-
-
Texas
-
Bellaire, Texas, United States, 77401
- Recruiting
- Houston Clinical Trials
-
Principal Investigator:
- Alain Katic, MD
-
Contact:
- Johnny Timmons
- Phone Number: 713-517-8993
- Email: jtimmons@houstonclintrials.com
-
Plano, Texas, United States, 75093
- Recruiting
- AIM Trials
-
Principal Investigator:
- Sejal Mehta, Ph.D
-
Contact:
- Jordan Yauch
- Phone Number: 972-267-1988
- Email: jordan.yauch@aimtrials.com
-
San Antonio, Texas, United States, 78229
- Recruiting
- Flourish Research
-
Principal Investigator:
- Kerry D Jesus, MS
-
Contact:
- Andrea Gomez
- Phone Number: 210-949-0122
- Email: agomez@flourishresearch.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 12 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- In Cohort 1, subjects must be at least 4 years old and less than 5 years and 10 months at Screening; in Cohort 2, subjects must be at least 6 years old and less than 12 years and 10 months at Screening.
- Subjects must have a body weight within the 5th and 95th percentile according to the gender-specific weight-for-age percentile charts from the Centers for Disease Control and Prevention (CDC). See calculator at https://www.infantchart.com/child/.
- Female subjects must agree, if they are of childbearing potential at Screening or when they become of childbearing potential during the study, to remain abstinent or agree to use an effective and medically acceptable form of birth control from the time of written or verbal assent to at least 14 days after the last dose of study drug. Childbearing potential is defined as follows: Girls under the age of 12 who have not had their first period will be considered "not of child-bearing potential." Girls 12 years of age (including girls who will become 13 years during the study) will be considered "of child-bearing potential," even if they have not yet had their first period. Irrespective of age, girls who have had their first period, will be considered "of child-bearing potential."
- Subjects must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical examinations, vital signs, electrocardiograms (ECGs), medical history, and clinical laboratory values (chemistry, hematology, urinalysis) at Screening. If any of the chemistry or hematology tests are not within the laboratory's reference range, then the subject can be included only if the Investigator determines the deviations to be not clinically relevant.
- At least one parent/legal guardian of the subject must voluntarily give written permission for him/her to participate in the study.
- Subjects in Cohort 2 must give written or verbal assent prior to study participation. For verbal assent, the procedure will be documented and signed by a witness. A parent or guardian may not be the witness for a child's verbal assent document.
- Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive presentation) per clinical evaluation and confirmed by Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI Kid).
- Subject has had ADHD symptoms present for at least 6 months prior to the Screening Visit.
- Subject must be able and willing to wash out current stimulant ADHD medications, including herbal medications, from 5 days prior to the start of the Treatment Period, and abstain from taking these to the end of Visit 6 or ET; and wash out non-stimulant ADHD medications from 14 days prior to the start of the Treatment Period, and abstain from taking these to the end of Visit 6.
- Subject must have a score of ≥4 (Moderately Ill) on the clinician-administered Clinical Global Impressions-Severity (CGI-S) scale. For subjects requiring washout of ADHD medications, this criterion refers to a score following washout.
- Subjects must have age and sex adjusted ratings of ≥90th percentile Total Score on the ADHD-Rating Scale (ADHD-RS) rated over the past 6 months (for 4- and 5-year old children, use Preschool Version of ADHD-RS-IV; for 6-12 years old children, use ADHD-RS-5).
- Subject functions at an age-appropriate level intellectually, as determined by the Investigator.
- Subject must have a systolic and diastolic blood pressure below the 95th percentile for age and gender according to the 2017 AAP guidelines (Flynn 2017) based on the average of 3 measurements 2-5 minutes apart.
- Subject, subject's parent/legal guardian, and caregiver (if applicable) must understand and be willing and able to comply with all study procedures and visit schedule.
- Subject, parent/legal guardian, and caregiver (if applicable) must be able to speak and understand English or Spanish and be able to communicate satisfactorily with the Investigator and study coordinator.
Exclusion Criteria:
- If female, must not be pregnant or breastfeeding, and if of childbearing potential, must have a negative urine pregnancy test at the start of the Screening Period. In addition, a positive pregnancy test before the last dose of study drug will result in early termination from the study.
- Subject with any clinically significant chronic medical condition that, in the judgment of the Investigator, may interfere with the participant's ability to participate in the study.
- Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the study as long as ODD is not the primary focus of treatment, and, in the opinion of the Investigator, the ODD is mild to moderate, and eligible subjects with ODD are appropriate and cooperative during Screening.
- Subject has generalized anxiety disorder or panic disorder that has been the primary focus of treatment at any time during the 12 months prior to Screening or that has required pharmacotherapy any time during the 6 months prior to Screening.
- Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, depression, vascular disorder, potential CNS-related disorders that might occur in childhood (e.g., Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders), or history of persistent neurological symptoms attributable to serious head injury.
- Subject taking anticonvulsants for seizure control or antidepressants currently or within the past 2 years before Screening are not eligible for study participation. A past history of febrile seizure or drug-induced seizure is allowed.
- Subject has a current (last month) psychiatric diagnosis other than specific phobia, motor skills disorders, ODD, sleep disorders, elimination disorders, adjustment disorders, learning disorders, or communication disorders. Subjects allowed to enroll with any of these DSM disorders will require written justification from the Investigator documenting why the conditions will not interfere with participation and to emphasize that ADHD is the primary indication.
- In the opinion of the Investigator, subject has clinically significant suicidal ideation/behavior, based on history of attempted suicide and the Columbia-Suicide Severity Rating Scale (C-SSRS) assessment at Screening.
- Subject has any clinically significant unstable medical abnormality, chronic disease (including asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular (including cardiomyopathy, serious arrhythmias, structural cardiac disorders, or severe hypertension), gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition (e.g., malabsorption, gastrointestinal surgery) that may interfere with absorption, distribution, metabolism, or excretion of study drug. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the medical monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during Screening.
- Subject has a history or presence of abnormal ECGs, which in the Investigator's opinion is clinically significant.
- Subject has a history of, or currently has, a malignancy.
- Subject has uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.
- Subject has greater than trace proteinuria in the urinalysis at Screening. Subjects with greater than trace proteinuria in the urinalysis at Screening but with a urine protein to creatinine (UP/C) ratio <0.2 in a first morning void urine sample will not be excluded from enrollment.
- Subjects has a current or recent (past 12 months) history of drug abuse; or current or recent history of drug abuse in someone living in the subject's home, or are using or planning to use prohibited drugs during the trial as specified in the protocol.
- Subject has a positive urine drug screen at Screening. Subjects with a positive methylphenidate (MPH) urine drug screen may be allowed to continue in the study, provided that the Investigator determines that the positive test is a result of taking prescribed medications and subject is willing to wash out the current medication as required.
- Subject has participated in any other clinical study with an investigational drug/product within 30 days or at least 5 half-lives, whichever is longer, prior to Screening.
- Subject has taken ADHD medications from more than one class within 30 days prior to Screening. Subjects on a stable dose of one ADHD medication with occasional use of ADHD medications from another class are eligible at the discretion of the Investigator.
- Subjects with demonstrated lack of response or intolerability to adequate dose and duration of treatment with MPH products. Judgment of adequate dose and duration is at the discretion of the Investigator.
- Subject has a positive urine MPH screen by dipstick (e.g., NarcoCheck®) at Visit 2.
- Subject is planning to initiate psychotherapy during the study (subjects participating in psychotherapy beginning at least 4 weeks before study initiation are permitted to continue).
- Subject has a history of severe allergies or adverse drug reactions to more than one class of medications.
- Subject has a history of allergic reaction or a known or suspected sensitivity to MPH or any substance that is contained in the study drug.
- Subject, parent/legal guardian, and caregiver (if applicable, at the Investigator's discretion) has commitments during the study that would interfere with attending study visits.
- Subject or subject's family anticipates a move outside the geographic range of the investigative site during the study period, or plans extended travel inconsistent with the recommended visit interval during study duration.
- Subject has one or more siblings living in the same household who are enrolled in this or another clinical drug trial.
- Subject shows evidence of current physical, sexual, or emotional abuse.
- Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: SDX/d-MPH in 4-5 year old
13.1 mg/2.6 mg SDX/d-MPH, 26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH
|
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
|
Placebo Comparator: Cohort 1: Placebo in 4-5 year old
matching placebo
|
matching placebo
|
Experimental: Cohort 2: SDX/d-MPH in 6-12 year old
26.1 mg/5.2 mg SDX/d-MPH, 39.2 mg/7.8 mg SDX/d-MPH, 52.3 mg/10.4
mg SDX/d-MPH
|
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
|
Placebo Comparator: Cohort 2: Placebo in 6-12 year old
matching placebo
|
matching placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A comparison of the change in mean ADHD Rating Scale (ADHD-RS) results from baseline to end of treatment between active and placebo treatments.
Time Frame: 4 weeks
|
The ADHD-RS is an 18-item scale based on Diagnostic and Statistical Manual of Mental Disorders criteria of ADHD that rates symptoms on a 4-point scale.
Each item is scored using a combination of severity and frequency ratings from a range of 0 (reflecting no symptoms or a frequency of never or rarely) to 3 (reflecting severe symptoms or a frequency of very often), so that the total ADHD-RS scores range from 0 to 54. Scores will be obtained during a clinician-directed interview with the parent/guardian/caregiver at each visit.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A comparison of the change in mean Clinical Global Impressions-Severity (CGI-S) results from baseline to end of treatment between active and placebo treatments.
Time Frame: 4 weeks
|
The CGI-S is a clinician-rated scale that evaluates the severity of psychopathology (ADHD symptoms in the study) on a scale from 1 (not at all ill) to 7 (among the most severely ill).
|
4 weeks
|
A comparison of the change in mean Clinical Global Impressions-Improvement (CGI-I) results from Visit 3 to end of treatment between active and placebo treatments.
Time Frame: 3 weeks
|
The CGI-I is a clinician-rated scale that evaluates the improvement of psychopathology (ADHD symptoms in the study) on a scale from 1 (very much improved) to 7 (very much worse).
|
3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ann Childress, MD, Center for Psychiatry and Behavioral Medicine Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2023
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
December 13, 2022
First Submitted That Met QC Criteria
January 5, 2023
First Posted (Actual)
January 17, 2023
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 4, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Dexmethylphenidate Hydrochloride
Other Study ID Numbers
- KP415.P01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit/Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
-
Massachusetts General HospitalShireActive, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States